Investors with an interest in Medical Services stocks have likely encountered both Elevance Health (ELV) and HealthEquity (HQY) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate re ...

Elevance Health - Elevance Health是医疗行业的一员，拥有Zacks Sector Rank排名第5[2] - Elevance Health目前的Zacks Rank为2（买入），显示其盈利前景较为乐观[3] - Elevance Health今年以来的回报率为0.4%，表现优于医疗行业平均回报率-0.7%[5] - Elevance Health属于医疗服务行业，今年以来的回报率优于该行业平均回报率-6.3%[8] Axonics Modulation Technologies - Axonics Modulation Technologies是另一家医疗股票，今年以来表现优于行业，回报率为9.8%[6] - Axonics Modulation Technologies当前的Zacks Rank为1（强烈买入），盈利预期增长186.5%[7] - Axonics Modulation Technologies属于医疗信息系统行业，该行业今年以来回报率增长18.2%[9] - 投资者应继续关注Elevance Health和Axonics Modulation Technologies，因为它们可能会保持良好的表现[10]

Elevance Health, Inc. (ELV) is positioned for growth with premium rate adjustments in the Health Benefits business, an expanding external pharmacy membership base and overall strength in the Carelon business. The BioPlus acquisition is expected to continue supporting the Carelon unit’s performance.Elevance — with a market cap of $111.6 billion — is one of the largest publicly traded health benefits companies in the United States. Courtesy of solid prospects, this currently Zacks Rank #3 (Hold) stock is wort ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Scores?T ...

The most recent trading session ended with Elevance Health (ELV) standing at $475.12, reflecting a -1.49% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.08%. Elsewhere, the Dow saw a downswing of 0.31%, while the tech-heavy Nasdaq appreciated by 0.02%.The the stock of health insurer has risen by 0.51% in the past month, lagging the Medical sector's gain of 6.57% and the S&P 500's gain of 3.52%.Analysts and investors alike will be keeping a close eye on the per ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as we ...

ELV的合作与服务 - ELV宣布将为符合条件的Medicaid健康计划参与者提供高质量智能手机，包括无限短信、通话和数据服务，增强ELV的服务[1] - ELV与Verizon、AT&T、T-Mobile和Samsung合作，通过Affordable Connectivity Program获得资金，为会员提供高质量服务，帮助弥合拥有智能手机和没有智能手机的人之间的鸿沟[2] ELV的新计划 - ELV的新计划将在2024年在多个州推出，旨在扩大覆盖范围，帮助减少医疗不平等，服务更多人群[3]

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health (NYSE: ELV) today announced that it has entered into an agreement to acquire Paragon Healthcare, Inc., a company specializing in life-saving and life-giving infusible and injectable therapies. For more than 20 years, Paragon Healthcare has provided infusion services to patients through its omnichannel model of ambulatory infusion centers, home infusion pharmacies, and other specialty pharmacy services. The company, headquartered in Plano, Texas, provides hig ...

Elevance Health, Inc. (NYSE:ELV) Q3 2023 Earnings Conference Call October 18, 2023 8:30 AM ET Company Participants Steve Tanal - VP of IR Gail Boudreaux - President and CEO John Gallina - CFO Peter Haytaian - President of Carelon Morgan Kendrick - President of Commercial and Specialty Health Benefits Division Felicia Norwood - President of Government Health Benefits Division Conference Call Participants A.J. Rice - UBS Nathan Rich - Goldman Sachs Stephen Baxter - Wells Fargo Ben Hendrix - RBC Capital Market ...

公司业务 - Elevance Health是一家致力于改善人类健康的健康公司，截至2023年9月30日，通过附属健康计划为超过4700万医疗会员提供服务[1] - Elevance Health将品牌组合整合为Anthem Blue Cross/Anthem Blue Cross and Blue Shield，Wellpoint和Carelon三大核心营销品牌[1] - Elevance Health的业务发展策略从传统的健康保险公司转变为终身信赖的健康伙伴，对业务进行了调整和管理，从2023年第一季度开始报告四个可报告部门的运营结果[2] - Elevance Health现在报告的四个可报告部门分别为Health Benefits、CarelonRx、Carelon Services和Corporate & Other，与之前的报告部门有所调整[4] - Elevance Health决定扩大在个人州或联邦辅助市场的参与，2023年在143个评级地区中提供个人公共交换产品，预计随着不再符合医疗补助资格的医疗保险会员继续退出医疗补助计划并寻求其他覆盖方式，公共交换会员数量有望增长[5] - Elevance Health的CarelonRx子公司向全国附属健康计划客户提供药房服务，包括处方管理、药房网络、特殊和送货上门的药房服务等，与CaremarkPCS Health, L.L.C.签订了为期五年的协议，预计2024年底到期[5] 财务表现 - 截至2023年9月30日，总医疗会员略有增加，主要受到BlueCard业务的增长以及个人公共交换和医疗保险优势产品的增长推动[6] - 截至2023年9月30日，营业收入为424.8亿美元，较2022年同期增加7.2%[6] - 截至2023年9月30日，净收入为13亿美元，较2022年同期减少18.6%[6] - 截至2023年9月30日，每股摊薄收益为5.45美元，较2022年同期减少17.7%[6] - 截至2023年9月30日，医疗会员总数为47,325，较2022年同期增加0.1%[9] - 截至2023年9月30日，其他会员中，牙科会员增加，生活和残疾会员减少[9] - 截至2023年9月30日，运营现金流为110.32亿美元，较2022年同期增加11.5%[8] - 截至2023年9月30日，总营业收入为1277.55亿美元，较2022年同期增加10.1%[11] - 截至2023年9月30日，净投资收入为12.96亿美元，较2022年同期增加16.5%[11] 风险提示 - 公司提到了COVID-19对业务的影响，包括大规模医疗紧急情况可能带来的影响[29] - 公司强调了信息技术中断的风险[29] - 公司提到了与医疗事故或专业责任索赔相关的风险[29] - 公司谈到了与并购、联合企业和战略联盟相关的风险[29]